287192-97-6

Basic information

• Product Name: 1-Boc-4-ethynylpiperidine
• Synonyms: TERT-BUTYL 4-ETHYNYLPIPERIDINE-1-CARBOXYLATE;1-Boc-4-ethynylpiperidine;4-Ethynyl-piperidine-1-carboxylic acid tert-butyl ester;Tert-butyl4-ethynylpiperidin-1-carboxylate;ert-butyl4-ethynylpiperidine-1-carboxylate;1-Piperidinecarboxylic acid, 4-ethynyl-, 1,1-dimethylethyl ester
• CAS NO: 287192-97-6
• Molecular Formula: C₁₂H₁₉NO₂
• Molecular Weight: 209.28
• Product Categories: pharmacetical
• Mol File: 287192-97-6.mol
• Article Data: 27

Chemical Properties

• Boiling Point: 269.583 °C at 760 mmHg
• Flash Point: 116.84 °C
• Appearance: /
• Density: 1.026 g/cm³
• Vapor Pressure: 0.007mmHg at 25°C
• Refractive Index: 1.491
• Storage Temp.: 2-8°C
• PKA: -2.20±0.40(Predicted)
• CAS DataBase Reference: 1-Boc-4-ethynylpiperidine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Boc-4-ethynylpiperidine(287192-97-6)
• EPA Substance Registry System: 1-Boc-4-ethynylpiperidine(287192-97-6)

Safety Data

• Hazardous Substances Data: 287192-97-6(Hazardous Substances Data)

Usage

Physical Form

Solid

Uses

tert-Butyl 4-Ethynylpiperidine-1-carboxylate is a useful research chemical.

InChI:InChI=1/C12H19NO2/c1-5-10-6-8-13(9-7-10)11(14)15-12(2,3)4/h1,10H,6-9H2,2-4H3

Upstream product

• 90965-06-3 dimethyl 1-(1-diazo-2-oxopropyl)phosphonate 
• 137076-22-3 tert butyl 4-formylpiperidine-1-carboxylate 
• 96854-79-4 diazo(diethoxyphosphoryl)acetic acid methyl ester 
• 203664-61-3 4-(2,2-dibromo-vinyl)-piperidine-1-carboxylic acid tert-butyl ester 
• 67-56-1 methanol 
• 1604039-50-0 tert-butyl 4-((trimethylsilyl)ethynyl)piperidine-1-carboxylate 
• 301673-14-3 tert-butyl 4-iodopiperidine-1-carboxylate 

Downstream Products

• 738577-08-7 4-ethynylpiperidine 
• 885609-18-7 4-(3-phenylisoxazol-5-yl)piperidine-1-carboxylic acid tert-butyl ester 
• 879399-83-4 4-(3-oxo-but-1-ynyl)-piperidine-1-carboxylic acid tert-butyl ester 
• 848411-82-5 (3-{4-[5-(2,3-dichloro-4-triisopropylsilanyloxy-phenyl)-2-methyl-2H-pyrazol-3-yl]-piperidine-1-sulfonylamino}-propyl)-methyl-carbamic acid tert-butyl ester 
• 848411-85-8 5-[4-(5-{1-[3-(tert-butoxycarbonyl-methyl-amino)-propylsulfamoyl]-piperidin-4-yl}-1-methyl-1H-pyrazol-3-yl)-2,3-dichloro-phenoxymethyl]-furan-2-carboxylic acid 
• 848411-83-6 5-[4-(5-{1-[3-(tert-butoxycarbonyl-methyl-amino)-propylsulfamoyl]-piperidin-4-yl}-1-methyl-1H-pyrazol-3-yl)-2,3-dichloro-phenoxymethyl]-furan-2-carboxylic acid ethyl ester 
• 515846-36-3 (R)-[1-(2-{4-[5-(2,3-dichloro-4-hydroxy-phenyl)-2-methyl-2H-pyrazol-3-yl]-piperidin-1-yl}-2-oxo-ethylcarbamoyl)-3-methyl-butyl]-carbamic acid tert-butyl ester 
• 515846-52-3 (R)-[1-(2-{4-[5-(2,3-dichloro-4-methoxy-phenyl)-2-methyl-2H-pyrazol-3-yl]-piperidin-1-yl}-2-oxo-ethylcarbamoyl)-3-methyl-butyl]-carbamic acid tert-butyl ester 
• 515846-33-0 (R)-[1-(2-{4-[3-(2,3-dichloro-4-triisopropylsilanyloxy-phenyl)-3-oxo-prop-1-ynyl]-piperidin-1-yl}-2-oxo-ethylcarbamoyl)-3-methyl-butyl]-carbamic acid tert-butyl ester 
• 515846-35-2 (R)-[1-(2-{4-[5-(2,3-dichloro-4-triisopropylsilanyloxy-phenyl)-2-methyl-2H-pyrazol-3-yl]-piperidin-1-yl}-2-oxo-ethylcarbamoyl)-3-methyl-butyl]-carbamic acid tert-butyl ester 
• 515846-39-6 (R)-5-[4-(5-{1-[2-(2-tert-butoxycarbonylamino-4-methyl-pentanoylamino)acetyl]-piperidin-4-yl}-1-methyl-1H-pyrazol-3-yl)-2,3-dichloro-phenoxymethyl]furan-2-carboxylic acid methyl ester 
• 515846-48-7 (R)-3-[4-(5-{1-[2-(2-tert-butoxycarbonylamino-4-methyl-pentanoylamino)acetyl]-piperidin-4-yl}-1-methyl-1H-pyrazol-3-yl)-2,3-dichloro-phenoxymethyl]benzoic acid 
• 515846-59-0 (R)-4-[4-(5-{1-[2-(2-tert-butoxycarbonylamino-4-methyl-pentanoylamino)acetyl]-piperidin-4-yl}-1-methyl-1H-pyrazol-3-yl)-2,3-dichloro-phenoxymethyl]benzoic acid 
• 515846-42-1 (R)-5-[4-(5-{1-[2-(2-tert-butoxycarbonylamino-4-methyl-pentanoylamino)acetyl]-piperidin-4-yl}-1-methyl-1H-pyrazol-3-yl)-2,3-dichloro-phenoxymethyl]furan-2-carboxylic acid 

Relevant articles and documents

Design and synthesis of novel triazolo-lapatinib hybrids as inhibitors of breast cancer cells

A series of triazolo-lapatinib hybrids were synthesized via copper (II)-oxide nanoparticle (Cu2O-NP)-catalyzed azide-alkyne cycloaddition. The ability of these compounds to reduce the viability of breast cancer SKBR3 and SUM159 cells and stem cell-like KG-1a leukemia cells was subsequently evaluated. Compared with lapatinib, compounds 6c–f were more potent than lapatinib against the three cell lines. Next, the toxicity of compounds 6c–f was assessed in zebrafish. Compound 6d had comparable toxicity with lapatinib at 200 μM (mortality rate = 10 vs. 10%), and compound 6e had lower toxicity than lapatinib at 200 μM (mortality rate = 0 vs. 10%). Thus, compound 6e is a promising lead compound worthy of further investigation. [Figure not available: see fulltext.].

Novel RET inhibitors. Pharmaceutical composition and use thereof

The invention belongs to the field of medicines, and relates to a novel RET inhibitor, a pharmaceutical composition and application thereof. , The present invention relates to a compound represented by formula (I), a stereoisomer, a tautomer, an oxynitrid

SUBSTITUTED 1, 6-NAPHTHYRIDINE INHIBITORS OF CDK5

Disclosed are compounds having structural formula I, and related salts and pharmaceutical compositions. Also disclosed are therapeutic methods, e.g., of treating diseases and conditions such as kidney disease, kidney failure, kidney stones, or polycystic kidney disease, using the compounds of formula (I), and related salts and pharmaceutical compositions.